Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs J Scheltema

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
3-Year Freedom from Progression After <sup>68</sup>Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter TrialLouise Emmett, Reuben Tang, Rohan Nandurkar, et al.
Therapeutic Advances in Urology|June 21, 2019
Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequencesMatthijs J Scheltema, Tim J O'Brien, Willemien van den Bos, et al.
BJU International|August 5, 2024
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO studyBart Geboers, Matthijs J Scheltema, Jason Jung, et al.
BJU International|August 24, 2023
Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancerYves J L Bodar, Liselotte M S Boevé, Pim J van Leeuwen, et al.
BJU International|October 20, 2023
Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapyBart Geboers, Dennie Meijer, William Counter, et al.
European Urology Focus|May 16, 2022
Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation StudyBart Geboers, William Gondoputro, James E Thompson, et al.
European Urology Oncology|November 29, 2024
The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical ProstatectomyTimo F W Soeterik, Joris G Heetman, Rick Hermsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 2, 2025
External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancerTessa D Van Bergen, Arthur J A T Braat, Rick Hermsen, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
3-Year Freedom from Progression After <sup>68</sup>Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter TrialLouise Emmett, Reuben Tang, Rohan Nandurkar, et al.
Therapeutic Advances in Urology|June 21, 2019
Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequencesMatthijs J Scheltema, Tim J O'Brien, Willemien van den Bos, et al.
BJU International|August 5, 2024
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO studyBart Geboers, Matthijs J Scheltema, Jason Jung, et al.
BJU International|August 24, 2023
Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancerYves J L Bodar, Liselotte M S Boevé, Pim J van Leeuwen, et al.
BJU International|October 20, 2023
Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapyBart Geboers, Dennie Meijer, William Counter, et al.
European Urology Focus|May 16, 2022
Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation StudyBart Geboers, William Gondoputro, James E Thompson, et al.
European Urology Oncology|November 29, 2024
The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical ProstatectomyTimo F W Soeterik, Joris G Heetman, Rick Hermsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 2, 2025
External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancerTessa D Van Bergen, Arthur J A T Braat, Rick Hermsen, et al.
Pageof 4